HPV Associated Disorders Treatment Market Size

HPV Associated Disorders Treatment Market size is estimated at USD 20.7 billion in 2024 and is expected to reach USD 35.5 billion by the end of 2037, witnessing around 4.6% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of the HPV associated disorders treatment is assessed at USD 45.1 billion.

The HPV associated disorders treatment market is experiencing robust growth, driven by the rising prevalence of HPV-associated disorders, including cervical, anal, and oropharyngeal cancers, globally. Diagnostic advancements such as NGS and molecular testing, along with the development of targeted therapies and vaccines are expanding treatment options. For instance, in June 2020, Merck received the U.S. FDA approval for GARDASIL 9, for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. Furthermore, government initiatives promoting HPV vaccination and screening programs, especially in developed regions, are further fueling the HPV associated disorders treatment market growth.